Maze Therapeutics (MAZE)
Maze Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
7.5M
Short interest
settlement 2026-10-15
10.1
Days to cover
+4.0 days vs prior
60.0%
Short share of volume
2026-11-02
1,605
Fails to deliver
settlement 2026-10-01
Thu 5 Nov
Next earnings
estimated date
-$5.2M
Insider flow, 90 days
0 buys, 27 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 41 settlements in the table, 41 in the chart. JSONAs of 15 October 2026, short interest in MAZE is 7,527,939 shares, up 1,849,650 shares over the last month. Over the last 41 readings it ranged from 1,195,075 shares (14 February 2025) to 7,527,939 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 746K shares a day that is 10.1 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/maze" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 7,527,939 | +14.7% | 745,712 | 10.09 |
| 2026-09-30 | 6,565,330 | +15.6% | 1,080,934 | 6.07 |
| 2026-09-15 | 5,678,289 | -4.1% | 546,179 | 10.40 |
| 2026-08-31 | 5,918,321 | -1.2% | 368,764 | 16.05 |
| 2026-08-14 | 5,988,933 | +5.5% | 370,295 | 16.17 |
| 2026-07-31 | 5,678,545 | +2.8% | 357,598 | 15.88 |
| 2026-07-15 | 5,525,278 | -0.0% | 651,947 | 8.48 |
| 2026-06-30 | 5,527,117 | +36.2% | 1,028,368 | 5.37 |
| 2026-06-15 | 4,057,146 | +4.1% | 527,440 | 7.69 |
| 2026-05-29 | 3,897,022 | -1.4% | 442,125 | 8.81 |
| 2026-05-15 | 3,950,970 | -9.2% | 533,249 | 7.41 |
| 2026-04-30 | 4,349,436 | +14.6% | 770,868 | 5.64 |
| 2026-04-15 | 3,795,902 | -2.4% | 1,007,473 | 3.77 |
| 2026-03-31 | 3,890,308 | +8.3% | 1,615,820 | 2.41 |
| 2026-03-13 | 3,591,005 | +4.4% | 566,914 | 6.33 |
| 2026-02-27 | 3,438,552 | +2.5% | 332,322 | 10.35 |
| 2026-02-13 | 3,356,466 | +22.4% | 608,007 | 5.52 |
| 2026-01-30 | 2,741,979 | +6.3% | 465,420 | 5.89 |
| 2026-01-15 | 2,580,026 | -1.0% | 314,401 | 8.21 |
| 2025-12-31 | 2,605,655 | +17.1% | 499,038 | 5.22 |
| 2025-12-15 | 2,224,690 | +0.2% | 426,903 | 5.21 |
| 2025-11-28 | 2,220,820 | -8.9% | 388,477 | 5.72 |
| 2025-11-14 | 2,438,054 | +3.1% | 449,162 | 5.43 |
| 2025-10-31 | 2,363,802 | +2.5% | 272,925 | 8.66 |
| 2025-10-15 | 2,305,717 | -6.4% | 380,404 | 6.06 |
| 2025-09-30 | 2,463,784 | +50.8% | 740,935 | 3.33 |
| 2025-09-15 | 1,634,122 | -5.3% | 931,992 | 1.75 |
| 2025-08-29 | 1,725,065 | -3.0% | 408,304 | 4.22 |
| 2025-08-15 | 1,777,795 | +14.6% | 163,875 | 10.85 |
| 2025-07-31 | 1,551,452 | -20.1% | 149,467 | 10.38 |
| 2025-07-15 | 1,940,575 | -3.8% | 120,291 | 16.13 |
| 2025-06-30 | 2,016,488 | -6.0% | 131,134 | 15.38 |
| 2025-06-13 | 2,145,476 | +13.2% | 95,186 | 22.54 |
| 2025-05-30 | 1,895,303 | -6.5% | 80,458 | 23.56 |
| 2025-05-15 | 2,028,108 | -7.2% | 130,198 | 15.58 |
| 2025-04-30 | 2,184,270 | +0.2% | 255,577 | 8.55 |
| 2025-04-15 | 2,180,819 | -18.8% | 298,814 | 7.30 |
| 2025-03-31 | 2,684,331 | +46.1% | 390,030 | 6.88 |
| 2025-03-14 | 1,837,124 | +9.7% | 121,114 | 15.17 |
| 2025-02-28 | 1,675,268 | +40.2% | 221,072 | 7.58 |
| 2025-02-14 | 1,195,075 | +100.0% | 397,174 | 3.01 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of MAZE volume is 60.0%, up 2.8 points over the last five sessions. Over the last 30 readings it ranged from 31.3% (8 October 2026) to 87.6% (25 September 2026). The latest reading is in line with the 30-session average of 58.3%, on 126K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 75K | 126K | 60.0% | 1 |
| 2026-10-30 | 67K | 107K | 62.4% | 0 |
| 2026-10-29 | 78K | 154K | 50.4% | 0 |
| 2026-10-28 | 73K | 139K | 52.8% | 4,283 |
| 2026-10-27 | 137K | 267K | 51.2% | 8,935 |
| 2026-10-26 | 99K | 173K | 57.2% | 2 |
| 2026-10-23 | 158K | 240K | 65.7% | 1 |
| 2026-10-22 | 253K | 480K | 52.6% | 0 |
| 2026-10-21 | 283K | 481K | 58.9% | 0 |
| 2026-10-20 | 414K | 885K | 46.8% | 6,190 |
| 2026-10-19 | 346K | 715K | 48.4% | 0 |
| 2026-10-16 | 230K | 428K | 53.7% | 200 |
| 2026-10-15 | 135K | 249K | 54.1% | 701 |
| 2026-10-14 | 217K | 375K | 57.7% | 9,912 |
| 2026-10-13 | 168K | 253K | 66.5% | 127 |
| 2026-10-12 | 302K | 781K | 38.6% | 0 |
| 2026-10-09 | 143K | 318K | 45.0% | 0 |
| 2026-10-08 | 110K | 351K | 31.3% | 0 |
| 2026-10-07 | 148K | 357K | 41.5% | 0 |
| 2026-10-06 | 167K | 278K | 60.1% | 0 |
| 2026-10-05 | 194K | 239K | 81.2% | 0 |
| 2026-10-02 | 199K | 260K | 76.6% | 0 |
| 2026-10-01 | 148K | 204K | 72.7% | 3,578 |
| 2026-09-30 | 136K | 201K | 67.4% | 0 |
| 2026-09-29 | 171K | 287K | 59.5% | 0 |
| 2026-09-28 | 420K | 595K | 70.7% | 0 |
| 2026-09-25 | 353K | 403K | 87.6% | 0 |
| 2026-09-24 | 229K | 340K | 67.5% | 100 |
| 2026-09-23 | 575K | 893K | 64.4% | 1,861 |
| 2026-09-22 | 914K | 2.0M | 46.6% | 115 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 1 October 2026, the fails-to-deliver balance in MAZE is 1,605 shares, down 5,254 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (12 June 2026) to 62,407 shares (30 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-01 | 1,605 | $27.18 | $44K |
| 2026-09-16 | 6,859 | $24.23 | $166K |
| 2026-09-02 | 1,030 | $26.53 | $27K |
| 2026-09-01 | 2,250 | $26.57 | $60K |
| 2026-08-28 | 4,156 | $28.60 | $119K |
| 2026-08-27 | 270 | $29.58 | $8K |
| 2026-08-25 | 5,696 | $29.60 | $169K |
| 2026-08-21 | 5,794 | $28.93 | $168K |
| 2026-08-14 | 35 | $27.67 | $968 |
| 2026-08-07 | 106 | $28.53 | $3K |
| 2026-08-04 | 1,527 | $27.33 | $42K |
| 2026-07-27 | 40 | $27.68 | $1K |
| 2026-07-22 | 623 | $29.30 | $18K |
| 2026-07-17 | 8 | $27.17 | $217 |
| 2026-07-07 | 17,447 | $32.35 | $564K |
| 2026-07-02 | 817 | $29.81 | $24K |
| 2026-07-01 | 5,163 | $29.84 | $154K |
| 2026-06-30 | 62,407 | $29.00 | $1.8M |
| 2026-06-29 | 14,463 | $28.43 | $411K |
| 2026-06-26 | 38 | $27.02 | $1K |
| 2026-06-24 | 1,086 | $26.41 | $29K |
| 2026-06-23 | 10,187 | $25.57 | $260K |
| 2026-06-22 | 6,432 | $25.68 | $165K |
| 2026-06-15 | 243 | $24.05 | $6K |
| 2026-06-12 | 2 | $24.09 | $48 |
| 2026-06-03 | 1,004 | $24.29 | $24K |
| 2026-06-02 | 1,911 | $25.46 | $49K |
| 2026-06-01 | 488 | $26.46 | $13K |
| 2026-05-27 | 847 | $26.35 | $22K |
| 2026-05-21 | 7,815 | $25.03 | $196K |
Insider trades
SEC Form 4, newest first. JSONInsiders at MAZE reported 27 open-market sells worth $5.2M in the last 90 days and no open-market buys. Latest filing: Dandekar Atul (CSBO) on 2026-10-29.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-29 | Dandekar Atul | CSBO | Sell | 8K | $32.07 | $241K | 32K |
| 2026-10-29 | Dandekar Atul | CSBO | Exercise or conversion | 857 | $10.42 | $9K | 40K |
| 2026-10-29 | Dandekar Atul | CSBO | Exercise or conversion | 7K | $10.42 | $69K | 39K |
| 2026-10-01 | Coloma Jason V | Chief Executive Officer | Sell | 32K | $27.02 | $862K | 191K |
| 2026-10-01 | Coloma Jason V | Chief Executive Officer | Sell | 3K | $27.02 | $70K | 16K |
| 2026-10-01 | Bernstein Harold | President, R&D & CMO | Sell | 16K | $26.93 | $435K | 0 |
| 2026-10-01 | Bernstein Harold | President, R&D & CMO | Exercise or conversion | 16K | $10.42 | $168K | 16K |
| 2026-09-29 | Dandekar Atul | CSBO | Sell | 8K | $27.06 | $203K | 32K |
| 2026-09-29 | Dandekar Atul | CSBO | Exercise or conversion | 8K | $10.42 | $78K | 40K |
| 2026-09-04 | Bernstein Harold | President, R&D & CMO | Sell | 10K | $26.22 | $255K | 0 |
| 2026-09-03 | Dandekar Atul | CSBO | Sell | 36 | $25.81 | $929 | 32K |
| 2026-09-03 | Dandekar Atul | CSBO | Sell | 3K | $26.01 | $83K | 32K |
| 2026-09-03 | Courtney Phillips | GC and Corp. Secretary | Sell | 22 | $25.78 | $567 | 7K |
| 2026-09-03 | Courtney Phillips | GC and Corp. Secretary | Sell | 2K | $26.01 | $52K | 7K |
| 2026-09-03 | Coloma Jason V | Chief Executive Officer | Sell | 129 | $25.77 | $3K | 27K |
| 2026-09-03 | Coloma Jason V | Chief Executive Officer | Sell | 11K | $26.01 | $293K | 27K |
| 2026-09-03 | Bernstein Harold | President, R&D & CMO | Sell | 59 | $25.78 | $2K | 10K |
| 2026-09-03 | Bernstein Harold | President, R&D & CMO | Sell | 5K | $26.01 | $133K | 10K |
| 2026-09-02 | Dandekar Atul | CSBO | Sell | 391 | $27.12 | $11K | 36K |
| 2026-09-02 | Dandekar Atul | CSBO | Sell | 3K | $26.38 | $74K | 36K |
| 2026-09-02 | Courtney Phillips | GC and Corp. Secretary | Sell | 243 | $27.12 | $7K | 9K |
| 2026-09-02 | Courtney Phillips | GC and Corp. Secretary | Sell | 2K | $26.38 | $46K | 9K |
| 2026-09-02 | Coloma Jason V | Chief Executive Officer | Sell | 1K | $27.12 | $37K | 39K |
| 2026-09-02 | Coloma Jason V | Chief Executive Officer | Sell | 10K | $26.38 | $260K | 40K |
| 2026-09-02 | Bernstein Harold | President, R&D & CMO | Sell | 625 | $27.12 | $17K | 15K |
| 2026-09-02 | Bernstein Harold | President, R&D & CMO | Sell | 4K | $26.38 | $118K | 16K |
| 2026-09-01 | Dandekar Atul | CSBO | Exercise or conversion | 13K | $0.00 | $0 | 39K |
| 2026-09-01 | Courtney Phillips | GC and Corp. Secretary | Exercise or conversion | 11K | $0.00 | $0 | 11K |
| 2026-09-01 | Coloma Jason V | Chief Executive Officer | Exercise or conversion | 50K | $0.00 | $0 | 50K |
| 2026-09-01 | Coloma Jason V | Chief Executive Officer | Sell | 32K | $26.29 | $839K | 223K |
| 2026-09-01 | Coloma Jason V | Chief Executive Officer | Sell | 3K | $26.31 | $68K | 18K |
| 2026-09-01 | Bernstein Harold | President, R&D & CMO | Exercise or conversion | 20K | $0.00 | $0 | 20K |
| 2026-09-01 | Bernstein Harold | President, R&D & CMO | Sell | 16K | $26.36 | $426K | 0 |
| 2026-09-01 | Bernstein Harold | President, R&D & CMO | Exercise or conversion | 16K | $10.42 | $168K | 16K |
| 2026-08-28 | Dandekar Atul | CSBO | Sell | 8K | $27.58 | $207K | 26K |
| 2026-08-28 | Dandekar Atul | CSBO | Exercise or conversion | 8K | $10.42 | $78K | 34K |
| 2026-08-13 | Bernstein Harold | President, R&D & CMO | Sell | 16K | $27.61 | $446K | 0 |
| 2026-08-13 | Bernstein Harold | President, R&D & CMO | Exercise or conversion | 16K | $10.42 | $168K | 16K |
| 2026-08-03 | Coloma Jason V | Chief Executive Officer | Sell | 2K | $27.09 | $43K | 255K |
| 2026-08-03 | Coloma Jason V | Chief Executive Officer | Sell | 30K | $26.71 | $810K | 257K |
| 2026-08-03 | Coloma Jason V | Chief Executive Officer | Sell | 154 | $27.09 | $4K | 21K |
| 2026-08-03 | Coloma Jason V | Chief Executive Officer | Sell | 2K | $26.71 | $65K | 21K |
| 2026-07-29 | Dandekar Atul | CSBO | Sell | 400 | $27.89 | $11K | 26K |
| 2026-07-29 | Dandekar Atul | CSBO | Sell | 7K | $27.31 | $194K | 27K |
| 2026-07-29 | Dandekar Atul | CSBO | Exercise or conversion | 8K | $10.42 | $78K | 34K |
| 2026-07-01 | Coloma Jason V | Chief Executive Officer | Sell | 2K | $30.44 | $49K | 287K |
| 2026-07-01 | Coloma Jason V | Chief Executive Officer | Sell | 30K | $29.95 | $908K | 289K |
| 2026-07-01 | Coloma Jason V | Chief Executive Officer | Sell | 3K | $29.98 | $78K | 23K |
| 2026-07-01 | Bernstein Harold | President, R&D & CMO | Sell | 1K | $30.34 | $36K | 0 |
| 2026-07-01 | Bernstein Harold | President, R&D & CMO | Sell | 13K | $29.86 | $400K | 1K |
| 2026-07-01 | Bernstein Harold | President, R&D & CMO | Exercise or conversion | 15K | $10.42 | $152K | 15K |
| 2026-06-29 | Dandekar Atul | CSBO | Sell | 8K | $28.02 | $210K | 26K |
| 2026-06-29 | Dandekar Atul | CSBO | Exercise or conversion | 8K | $10.42 | $78K | 34K |
| 2026-06-23 | Coloma Jason V | Chief Executive Officer | Sell | 24K | $26.05 | $622K | 319K |
| 2026-06-22 | Coloma Jason V | Chief Executive Officer | Sell | 2K | $26.00 | $53K | 26K |
| 2026-06-22 | Coloma Jason V | Chief Executive Officer | Sell | 2K | $26.00 | $51K | 343K |
| 2026-06-01 | Coloma Jason V | Chief Executive Officer | Sell | 553 | $26.24 | $15K | 28K |
| 2026-06-01 | Coloma Jason V | Chief Executive Officer | Sell | 6K | $26.20 | $160K | 345K |
| 2026-06-01 | Bernstein Harold | President, R&D & CMO | Sell | 2K | $26.36 | $42K | 0 |
| 2026-06-01 | Bernstein Harold | President, R&D & CMO | Sell | 13K | $25.57 | $339K | 2K |
| 2026-06-01 | Bernstein Harold | President, R&D & CMO | Exercise or conversion | 15K | $10.42 | $155K | 15K |
| 2026-05-29 | Dandekar Atul | CSBO | Sell | 8K | $26.34 | $198K | 25K |
| 2026-05-29 | Dandekar Atul | CSBO | Exercise or conversion | 8K | $10.42 | $78K | 32K |
| 2026-05-26 | Coloma Jason V | Chief Executive Officer | Sell | 26K | $26.02 | $666K | 351K |
| 2026-05-22 | Coloma Jason V | Chief Executive Officer | Sell | 2K | $26.00 | $64K | 29K |
| 2026-05-22 | Coloma Jason V | Chief Executive Officer | Sell | 5K | $26.00 | $117K | 377K |
| 2026-05-15 | Coloma Jason V | Chief Executive Officer | Sell | 116 | $26.00 | $3K | 31K |
| 2026-05-15 | Coloma Jason V | Chief Executive Officer | Sell | 2K | $26.00 | $47K | 381K |
| 2026-05-14 | Bernstein Harold | President, R&D & CMO | Sell | 15K | $26.22 | $393K | 0 |
| 2026-05-14 | Bernstein Harold | President, R&D & CMO | Exercise or conversion | 15K | $10.42 | $156K | 15K |
| 2026-05-04 | HOMCY CHARLES J | Director | Gift | 7K | $0.00 | $0 | 31K |
| 2026-05-04 | Dandekar Atul | CSBO | Exercise or conversion | 6K | $10.42 | $62K | 25K |
| 2026-05-04 | Dandekar Atul | CSBO | Exercise or conversion | 8K | $10.42 | $87K | 19K |
| 2026-04-29 | Dandekar Atul | CSBO | Sell | 8K | $25.37 | $190K | 11K |
| 2026-04-29 | Dandekar Atul | CSBO | Exercise or conversion | 8K | $10.42 | $78K | 18K |
| 2026-04-01 | Bernstein Harold | President, R&D & CMO | Sell | 300 | $31.07 | $9K | 0 |
| 2026-04-01 | Bernstein Harold | President, R&D & CMO | Sell | 3K | $30.06 | $101K | 300 |
| 2026-04-01 | Bernstein Harold | President, R&D & CMO | Sell | 11K | $29.24 | $332K | 4K |
| 2026-04-01 | Bernstein Harold | President, R&D & CMO | Exercise or conversion | 15K | $10.42 | $156K | 15K |
| 2026-04-01 | Bachrodt Amy | SVP, Finance | Sell | 300 | $30.34 | $9K | 13K |
| 2026-04-01 | Bachrodt Amy | SVP, Finance | Sell | 2K | $29.32 | $65K | 13K |
| 2026-04-01 | Bachrodt Amy | SVP, Finance | Exercise or conversion | 3K | $10.42 | $26K | 15K |
| 2026-03-30 | Dandekar Atul | CSBO | Sell | 790 | $30.02 | $24K | 11K |
| 2026-03-30 | Dandekar Atul | CSBO | Sell | 7K | $29.26 | $196K | 11K |
| 2026-03-30 | Dandekar Atul | CSBO | Exercise or conversion | 8K | $10.42 | $78K | 18K |
| 2026-03-20 | Bernstein Harold | President, R&D & CMO | Sell | 5K | $50.02 | $252K | 0 |
| 2026-03-20 | Bernstein Harold | President, R&D & CMO | Sell | 4K | $49.32 | $187K | 5K |
| 2026-03-20 | Bernstein Harold | President, R&D & CMO | Sell | 6K | $48.20 | $297K | 9K |
| 2026-03-20 | Bernstein Harold | President, R&D & CMO | Exercise or conversion | 15K | $10.42 | $156K | 15K |
| 2026-03-10 | Bernstein Harold | President, R&D & CMO | Sell | 348 | $51.02 | $18K | 0 |
| 2026-03-10 | Bernstein Harold | President, R&D & CMO | Sell | 30K | $50.45 | $1.5M | 348 |
| 2026-03-10 | Bernstein Harold | President, R&D & CMO | Exercise or conversion | 30K | $10.42 | $313K | 30K |
| 2026-03-02 | Bachrodt Amy | SVP, Finance | Sell | 4K | $45.47 | $168K | 13K |
| 2026-03-02 | Bachrodt Amy | SVP, Finance | Sell | 1K | $44.44 | $58K | 17K |
| 2026-03-02 | Bachrodt Amy | SVP, Finance | Exercise or conversion | 5K | $10.42 | $52K | 18K |
| 2026-02-27 | Dandekar Atul | CSBO | Sell | 4K | $45.72 | $172K | 11K |
| 2026-02-27 | Dandekar Atul | CSBO | Sell | 4K | $45.13 | $169K | 14K |
| 2026-02-27 | Dandekar Atul | CSBO | Exercise or conversion | 8K | $10.42 | $78K | 18K |
| 2026-02-02 | Bernstein Harold | President, R&D & CMO | Sell | 100 | $47.23 | $5K | 0 |
| 2026-02-02 | Bernstein Harold | President, R&D & CMO | Sell | 6K | $46.37 | $275K | 100 |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON26 Form 144 notices on file for MAZE worth $27.7M at the prices reported; 10 in the last 90 days worth $5.3M. Latest: Coloma Jason V filed on 2026-11-02 to sell 34,501 shares ($1.1M) from 2026-11-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-11-02 | Coloma Jason VOfficer | 35K | $1.1M | 0.062% | 2026-11-02 | UBS Financial Services Inc. |
| 2026-10-29 | ATUL DANDEKAROfficer | 15K | $476K | 0.027% | 2026-10-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-10-01 | Coloma Jason VOfficer | 35K | $933K | 0.062% | 2026-10-01 | UBS Financial Services Inc. |
| 2026-10-01 | HAROLD BERNSTEINOfficer | 16K | $439K | 0.029% | 2026-10-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-04 | HAROLD BERNSTEINOfficer | 10K | $251K | 0.017% | 2026-09-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-02 | Atul DandekarOfficer | 7K | $177K | 0.012% | 2026-09-02 | Morgan Stanley Smith Barney LLC |
| 2026-09-02 | Courtney PhillipsOfficer | 4K | $110K | 0.007% | 2026-09-02 | Morgan Stanley Smith Barney LLC |
| 2026-09-02 | Jason V ColomaOfficer | 23K | $623K | 0.042% | 2026-09-02 | Morgan Stanley Smith Barney LLC |
| 2026-09-02 | Harold BernsteinOfficer | 11K | $284K | 0.019% | 2026-09-02 | Morgan Stanley Smith Barney LLC |
| 2026-09-01 | Coloma Jason VOfficer | 35K | $908K | 0.062% | 2026-09-01 | UBS Financial Services Inc. |
| 2026-08-03 | Coloma Jason VOfficer | 35K | $923K | 0.062% | 2026-08-03 | UBS Financial Services Inc. |
| 2026-07-29 | ATUL DANDEKAROfficer | 23K | $627K | 0.041% | 2026-07-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-01 | Coloma Jason VOfficer | 35K | $1.0M | 0.062% | 2026-07-01 | UBS Financial Services Inc. |
| 2026-07-01 | HAROLD BERNSTEINOfficer | 47K | $1.4M | 0.085% | 2026-07-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-01 | Coloma Jason VOfficer | 35K | $908K | 0.062% | 2026-06-01 | UBS Financial Services Inc. |
| 2026-05-15 | Coloma Jason VOfficer | 35K | $895K | 0.062% | 2026-05-15 | UBS Financial Services Inc. |
| 2026-03-30 | ATUL DANDEKAROfficer | 30K | $911K | 0.060% | 2026-03-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-10 | HAROLD BERNSTEINOfficer | 75K | $3.4M | 0.156% | 2026-03-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-16 | SEKAR KATHIRESANFormer Director | 30K | $1.2M | 0.062% | 2026-01-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-07 | CATHERINE SOHNDirector | 27K | $1.1M | 0.056% | 2026-01-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-06 | CATHERINE SOHNDirector | 2K | $96K | 0.005% | 2026-01-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-29 | ATUL P DANDEKAROfficer | 88K | $3.7M | 0.182% | 2025-12-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-29 | HAROLD BERNSTEINOfficer | 105K | $4.4M | 0.218% | 2025-12-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-04 | SEKAR KATHIRESANFormer Board Member | 10K | $425K | 0.021% | 2025-12-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-21 | SEKAR KATHIRESANFormer Board Member | 28K | $985K | 0.057% | 2025-11-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-15 | RICHARD SCHELLERDirector | 21K | $464K | 0.047% | 2025-09-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON8 holders report 5% or more of MAZE in their latest filing, all on Schedule 13G (passive). The largest reported stake is TRV GP IV, LLC at 9.3% of the class (4,473,958 shares), filed 2026-02-13 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 1 | Paradigm BioCapital Advisors GP LLCother entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Paradigm BioCapital Advisors LPpartnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Senai Asefaw, M.D.individual | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Paradigm BioCapital International Fund Ltd.corporation | 0 | 0.0% | 2026-06-30 |
| 2026-07-29 | 13G | BlackRock, Inc.parent holding company | 3.0M | 5.4% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 3 | JANUS HENDERSON GROUP PLCparent holding company | 2.9M | 5.8% | 2026-03-31 |
| 2026-02-13 | 13G/Ano. 4 | FHMLSP, L.L.C.other entity | 4.3M | 9.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | Frazier Life Sciences Public Fund, L.P.partnership | 4.3M | 9.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | FHMLSP, L.P.partnership | 4.3M | 9.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | FHMLS XI, L.L.C.other entity | 149K | 0.3% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | FHMLS XI, L.P.partnership | 149K | 0.3% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | Frazier Life Sciences XI, L.P.partnership | 149K | 0.3% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | James N. Topperindividual | 76K | 0.2% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | Patrick J. Heronindividual | 76K | 0.2% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | FHMLS X, L.L.C.other entity | 76K | 0.2% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | FHMLS X, L.P.partnership | 76K | 0.2% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | Frazier Life Sciences X, L.P.partnership | 76K | 0.2% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | Frazier Life Sciences XII, L.P.partnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | FHMLS XII, L.P.partnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | FHMLS XII, L.L.C.other entity | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 1 | TRV GP IV, LLCother entity | 4.5M | 9.3% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 1 | Third Rock Ventures GP IV, L.P.partnership | 4.5M | 9.3% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 1 | Third Rock Ventures IV, L.P.partnership | 4.5M | 9.3% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 1 | Third Rock Ventures V, L.P.partnership | 951K | 2.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 1 | Third Rock Ventures GP V, L.P.partnership | 951K | 2.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 1 | TRV GP V, LLCother entity | 951K | 2.0% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 1 | Alphabet Inc.parent holding company, corporation | 1.4M | 2.9% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 1 | XXVI Holdings Inc.corporation | 1.4M | 2.9% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 1 | Alphabet Holdings LLCother entity | 1.4M | 2.9% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 1 | GV 2019, L.P.partnership | 784K | 1.6% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 1 | GV 2019 GP, L.P.partnership | 784K | 1.6% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 1 | GV 2019 GP, L.L.C.other entity | 784K | 1.6% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 1 | GV 2023 GP, L.L.C.other entity | 605K | 1.3% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 1 | GV 2023 GP, L.P.partnership | 605K | 1.3% | 2025-12-31 |
| 2026-02-06 | 13G/Ano. 1 | GV 2023, L.P.partnership | 605K | 1.3% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 1 | James Tananbaumindividual | 609K | 1.4% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Foresite Capital Fund IV, L.P.partnership | 523K | 1.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Foresite Capital Management IV, LLCother entity | 523K | 1.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Foresite Capital Management V, LLCother entity | 86K | 0.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Foresite Capital Fund V, L.P.partnership | 86K | 0.2% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 1 | Matrix Capital Management Company, LPinvestment adviser, partnership | 1.7M | 3.5% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 1 | DAVID E. GOELparent holding company, individual | 1.7M | 3.5% | 2025-09-30 |
13F holders
Tracked managers holding MAZE at their latest 13F. JSON4 of the 30 tracked managers held MAZE at their latest 13F, $32.4M in total at quarter-end prices. Citadel Advisors is the largest at $25.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 853K | $25.4M | 0.00% | +77K |
| Two Sigma Investments | 2026-06-30 | 193K | $5.8M | 0.00% | +177K |
| AQR Capital Management | 2026-06-30 | 27K | $810K | 0.00% | -784 |
| D. E. Shaw & Co. | 2026-06-30 | 12K | $359K | 0.00% | -34K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Maze Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Maze Therapeutics (MAZE), SEC CIK 1842295, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-01.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-11-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-29.JSON and CSV
- Company record
- EDGAR filing index for CIK 1842295Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of MAZE is sold short?
7,527,939 shares were held short at the 2026-10-15 settlement, 10.1 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is MAZE's daily short volume?
On 2026-11-02, 75,366 of the 125,601 MAZE shares reported to FINRA were sold short, 60.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does MAZE have fails to deliver?
The SEC's latest file shows 1,605 MAZE shares failed to deliver at settlement 2026-10-01. Fails are reported per settlement date and published twice a month with a lag.
Are MAZE insiders buying or selling?
Insiders at MAZE reported 27 open-market sells worth $5.2M in the last 90 days and no open-market buys. Latest filing: Dandekar Atul (CSBO) on 2026-10-29.
Have MAZE insiders filed to sell?
26 Form 144 notices on file for MAZE worth $27.7M at the prices reported; 10 in the last 90 days worth $5.3M. Latest: Coloma Jason V filed on 2026-11-02 to sell 34,501 shares ($1.1M) from 2026-11-02.
Who owns 5% or more of MAZE?
8 holders report 5% or more of MAZE in their latest filing, all on Schedule 13G (passive). The largest reported stake is TRV GP IV, LLC at 9.3% of the class (4,473,958 shares), filed 2026-02-13 for an event on 2025-12-31.
Which tracked 13F managers own MAZE?
4 of the 30 tracked 13F managers held MAZE shares at their latest filing, $32.4M in all. The largest: Ken Griffin's Citadel Advisors (853K shares, $25.4M), Two Sigma Investments (193K shares, $5.8M), Cliff Asness's AQR Capital Management (27K shares, $810K), D. E. Shaw & Co. (12K shares, $359K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.